SCHEMBL4839710

SCHEMBL4839710

Cc1[nH]c2ccccc2c1C1CCN(CCC2c3ccccc3CCN2C(=O)c2ccc3nonc3c2)CC1

nearest known ligand 0.43

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.38
KCNH2 Q12809 1/20 0.37
HDAC1 Q13547 1/20 0.37
HTR1D P28221 1/20 0.36
HTR1B P28222 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4839745 0.81 MCHR1 (0.46)
SCHEMBL4833317 0.80 ALDH1A1 (0.47) KCNH2HDAC1
SCHEMBL4837834 0.80 HTR1D (0.41) HSD11B1HTR1DHTR1B
SCHEMBL4837481 0.79 KCNH2 (0.42) KCNH2HDAC1
SCHEMBL4837490 0.79 NPSR1 (0.48) KCNH2HDAC1
SCHEMBL4839375 0.79 NPSR1 (0.48) KCNH2HDAC1
SCHEMBL4833361 0.79 TRPM8 (0.44) HSD11B1HDAC1
SCHEMBL4838414 0.76 HTR2A (0.42) KCNH2HDAC1
SCHEMBL4839706 0.76 KCNH2 (0.35) KCNH2HDAC1HTR1DHTR1B
SCHEMBL4832812 0.76 KCNH2 (0.38) KCNH2HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 HSD11B1 1314/4885KCNH2 24/4885HDAC1 2287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.